The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
02 09 2021
02 09 2021
Historique:
received:
11
02
2021
accepted:
09
04
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
The use of multiparametric prostate magnetic resonance imaging (mpMRI) is recommended, in the European Association of Urology (EAU) guidelines, for local staging of patients with prostate cancer (PCa). Systemic staging is recommended only for patients with unfavourable intermediate and high-risk disease; with bone and lymph node assessments usually being performed using bone scan (BS) and computed tomography (CT), respectively. Magnetic resonance imaging (MRI) is the imaging technique with the highest sensitivity for the detection of bone metastases and has shown promising results also for lymph node assessments. In this report we illustrate how MRI provided a comprehensive assessment of local disease as well as bone and lymph node metastases in a patient with PCa. (www.actabiomedica.it).
Identifiants
pubmed: 34487080
doi: 10.23750/abm.v92i4.11337
pmc: PMC8477117
doi:
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2021214Références
Eur Urol. 2017 Jan;71(1):81-92
pubmed: 27317091
Eur Urol. 2018 Jan;73(1):81-91
pubmed: 28412063
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Nat Rev Dis Primers. 2020 Oct 15;6(1):83
pubmed: 33060614
Eur Urol. 2019 Sep;76(3):340-351
pubmed: 30898406
Eur Urol. 2019 Jul;76(1):115-124
pubmed: 30826218
Eur Radiol. 2011 Dec;21(12):2604-17
pubmed: 21887484
Acta Oncol. 2016;55(1):59-67
pubmed: 25833330
Tumori. 2011 Sep-Oct;97(5):629-33
pubmed: 22158495
Skeletal Radiol. 2014 Nov;43(11):1503-13
pubmed: 24841276
N Engl J Med. 2004 Apr 15;350(16):1655-64
pubmed: 15084698
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Semin Nucl Med. 2005 Apr;35(2):135-42
pubmed: 15765376
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
J Magn Reson Imaging. 2008 Sep;28(3):714-9
pubmed: 18777531
J Urol. 2004 Jun;171(6 Pt 1):2122-7
pubmed: 15126770
Am J Med. 1997 Aug;103(2):134-45
pubmed: 9274897
Invest Radiol. 2010 Jan;45(1):15-23
pubmed: 19996762
Eur Urol Focus. 2018 Sep;4(5):686-693
pubmed: 28753806
Acad Radiol. 2008 May;15(5):641-6
pubmed: 18423322
Curr Mol Med. 2013 May;13(4):626-39
pubmed: 23061677
J Urol. 1958 Feb;79(2):339-42
pubmed: 13514887
J Cell Biochem. 2004 Mar 1;91(4):718-29
pubmed: 14991763
Eur Radiol. 2019 Jun;29(6):3159-3169
pubmed: 30519933
Semin Nucl Med. 2009 Nov;39(6):396-407
pubmed: 19801219
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
Prostate. 2014 May;74(5):469-77
pubmed: 24375774
Eur Urol. 2012 Jul;62(1):68-75
pubmed: 22366187
Gene. 2004 Oct 27;341:19-39
pubmed: 15474285
J Clin Oncol. 2020 Sep 1;38(25):2830-2838
pubmed: 32484754
J Clin Oncol. 2020 Jun 10;38(17):1963-1996
pubmed: 31940221
J Bone Oncol. 2012 Dec 11;2(1):47-57
pubmed: 26909265